Publications by authors named "Jean L Chan"

Claim this Profile
P
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Kyriakie Sarafoglou, Mimi S Kim, Maya Lodish, Eric I Felner, Laetitia Martinerie, Jean L Chan

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Richard J Auchus, Oksana Hamidi, Rosario Pivonello, Irina Bancos, Gianni Russo, Jean L Chan

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
Ron S Newfield, Kyriakie Sarafoglou, Patricia Y Fechner, Natalie J Nokoff, Richard J Auchus, Jean L Chan

J Clin Endocrinol Metab· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model.
Anahita Rabiee, Yanhong Deng, Maria Ciarleglio, Jean L Chan, Monica Pons

Hepatol Commun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
Richard J Auchus, Kyriakie Sarafoglou, Patricia Y Fechner, Maria G Vogiatzi, Erik A Imel, Jean L Chan

J Clin Endocrinol Metab· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis.
Ethan M Weinberg, Michael P Curry, Catherine T Frenette, Fredric G Regenstein, Eugene R Schiff, Jean L Chan

Liver Transpl· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Catherine Frenette, Zeid Kayali, Edward Mena, Parvez S Mantry, Kathryn J Lucas, Jean L Chan

J Hepatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
Mazen Noureddin, Jean L Chan, Katherine Barradas, Lara Dimick-Santos, Elmer Schabel

Gastroenterology· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A Harrison, Manal F Abdelmalek, Jean L Chan

J Hepatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Stephen A Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad H Younes, Jean L Chan

J Hepatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Catherine T Frenette, Giuseppe Morelli, Mitchell L Shiffman, R Todd Frederick, Raymond A Rubin, Jean L Chan

Clin Gastroenterol Hepatol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman, Brian B Borg, Nikolaos Pyrsopoulos, Jean L Chan

Hepatology· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Mitchell Shiffman, Bradley Freilich, Raj Vuppalanchi, Kymberly Watt, Jean L Chan

Aliment Pharmacol Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoma in acquired generalized lipodystrophy.
Rebecca J Brown, Jean L Chan, Elaine S Jaffe, Elaine Cochran, Alex M DePaoli

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Jean L Chan, Joy Koda, Joseph S Heilig, Elaine K Cochran, Phillip Gorden

Clin Endocrinol (Oxf)· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical approach to the detection of lipodystrophy - an AACE consensus statement.
Yehuda Handelsman, Elif A Oral, Zachary T Bloomgarden, Rebecca J Brown, Jean L Chan

Endocr Pract· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Jean L Chan, Karen Lutz, Elaine Cochran, Wenying Huang, Yvette Peters

Endocr Pract· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for leptin-replacement therapy for severe lipodystrophy.
Elif A Oral, Jean L Chan

Endocr Pract· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical classification and treatment of congenital and acquired lipodystrophy.
Jean L Chan, Elif A Oral

Endocr Pract· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development.
Jean L Chan, Jonathan D Roth, Christian Weyer

J Investig Med· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of the metabolic syndrome and type 2 diabetes through lifestyle modification.
Faidon Magkos, Mary Yannakoulia, Jean L Chan, Christos S Mantzoros

Annu Rev Nutr· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.
Lalita Khaodhiar, Aoife M Brennan, Christina Lima, Jean L Chan, Christos S Mantzoros

Metabolism· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans.
Aoife M Brennan, Jennifer H Lee, Sotirios Tsiodras, Jean L Chan, John Doweiko

Eur J Endocrinol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity.
Jean L Chan, Shekman L Wong, Christos S Mantzoros

Clin Pharmacokinet· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parathyroid carcinoma and neurofibromatosis.
Aram N Demirjian, Joseph M Grossman, Jean L Chan, Sareh Parangi

Surgery· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis